Skip to main content

Table 3 Subgroup analysis of the objective response rate (ORR), overall survival rate at 12 months (OS-12 m) and grade 3–4 adverse effects (grade 3–4 AEs) of B + E in patients with advanced HCC

From: Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies

 

ORR

OS-12 m

Group

N

ES (95% CI)

P Values

I2 (%)

N

ES (95% CI)

P Values

I2 (%)

Total

342

0.126 (0.063,0.190)

70.0%

298

0.437 (0.329,0.546)

72.6%

ECOG

 0–1

176

0.117 (0.009,0.224)

0.956

77.6%

176

0.376(.121,0.631)

0.701

85.1%

 0–2

166

0.140 (0.044,0.236)

73.3%

122

0.470 (0.351,0.589)

63.9%

Pre-schedule

 Prior systematic therapy

180

0.145 (0.044,0.247)

0.128

77.3%

136

0.443 (0.243, 0.644)

o.456

83.5%

 No systematic therapy

162

0.103 (0.015,0.191)

67.9%

162

0.408 (0.332, 0.483)

0.0%

Line of treatment

 First line

162

0.103 (0.015,0.191)

0.089

68.9%

162

0.408 (0.332, 0.483)

0.048

0.0%

 Second line

180

0.145 (0.044,0.247)

77.3%

37

0.267(−0.007,0.542)

83.5%

Region

 America

237

0.161 (0.068,0.258)

0.014

76.7%

237

0.481 (0.369,0.592)

0.517

65.2%

 Not America

105

0.071 (0.020,0.123)

0.0%

61

0.308(−0.036,0.652)

87.2%

Liver functions

 Child-Pugh class A/B

147

0.170 (0.019,0.321)

0.224

84.2%

147

0.524 (0.418,0.630)

< 0.001

40.5%

 Child-Pugh class A

195

0.098 (0.044,0.153)

38.4%

151

0.341 (0.179,0.503)

 

74.4%

  1. Note: Liver functions: the subgroup of Child-Pugh class A and B refers patients enrolled with liver function of Child-Pugh class B excess 10%, otherwise the subgroup of Child-Pugh class A. ES Effect size, ORR objective response rate, OS overall survival, AEs adverse effects, B + E bevacizumab combined with erlotinib